Scholarlink

Purpose of Review <p>This review presents a comprehensive synthesis of current knowledge on candidal intertrigo, encompassing its etiology, epidemiology, clinical features, diagnostic strategies, therapeutic options, and preventive measures. Emphasis is placed on the diagnostic challenges and the necessity of identifying and managing predisposing factors to achieve effective treatment and prevent recurrence.</p> Recent Findings <p>Emerging evidence highlights an increasing involvement of non-<i>albicans</i> and antifungal-resistant <i>Candida</i> species, particularly in at-risk populations. Recent advancements in diagnostic methodologies, including PCR and MALDI-TOF MS, have enhanced species-level identification, facilitating targeted interventions. Novel topical formulations, corticosteroid-antifungal combinations, and alternative therapies such as retinoids have shown promise in managing resistant cases.</p> Summary <p>Candidal intertrigo remains a common yet frequently overlooked superficial mycosis, particularly among individuals with metabolic or immunosuppressive conditions. Optimal management extends beyond antifungal treatment and requires addressing modifiable risk factors, promoting adequate hygiene, and ensuring environmental control. While most cases respond to topical agents, systemic therapy may be warranted in severe or recurrent infections. Ongoing advances in therapeutics and diagnostics offer the potential for more personalized and effective care. Preventive strategies are essential to minimizing relapse and associated morbidity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Candidal Intertrigo: Underdiagnosed Entity

  • 期刊论文

  • 发表日期：

    2025年8月6日

查看全文
  • Julieta Loya-Acosta,
  • Tania Carey Guzmán-Ochoa,
  • Andrés Tirado-Sánchez,
  • Paula Torres-Camacho,
  • Valeria Díaz-Molina,
  • Alexandro Bonifaz

摘要

Purpose of Review

This review presents a comprehensive synthesis of current knowledge on candidal intertrigo, encompassing its etiology, epidemiology, clinical features, diagnostic strategies, therapeutic options, and preventive measures. Emphasis is placed on the diagnostic challenges and the necessity of identifying and managing predisposing factors to achieve effective treatment and prevent recurrence.

Recent Findings

Emerging evidence highlights an increasing involvement of non-albicans and antifungal-resistant Candida species, particularly in at-risk populations. Recent advancements in diagnostic methodologies, including PCR and MALDI-TOF MS, have enhanced species-level identification, facilitating targeted interventions. Novel topical formulations, corticosteroid-antifungal combinations, and alternative therapies such as retinoids have shown promise in managing resistant cases.

Summary

Candidal intertrigo remains a common yet frequently overlooked superficial mycosis, particularly among individuals with metabolic or immunosuppressive conditions. Optimal management extends beyond antifungal treatment and requires addressing modifiable risk factors, promoting adequate hygiene, and ensuring environmental control. While most cases respond to topical agents, systemic therapy may be warranted in severe or recurrent infections. Ongoing advances in therapeutics and diagnostics offer the potential for more personalized and effective care. Preventive strategies are essential to minimizing relapse and associated morbidity.